Skip to content

Karen B. Jacobson, MD, MPH

Karen  Jacobson, MD, MPH

Dr. Karen Jacobson joined the Vaccine Study Center at the Kaiser Permanente Northern California Division of Research in 2023 as a Research Scientist. She is a board-certified Infectious Diseases physician.

Dr. Jacobson obtained a bachelor of arts in Human Biology from Stanford University and a doctor of medicine and master of Public Health from the Icahn School of Medicine at Mount Sinai. She completed her residency training in Internal Medicine/HIV Primary Care at the Yale-New Haven Hospital and her fellowship in Infectious Diseases at Stanford.

Dr. Jacobson’s research is focused on mitigating sequelae of infectious diseases, particularly SARS-CoV-2. She is co-Investigator of multiple outpatient studies of treatments for acute and convalescent SARS-CoV-2 disease, and her published work has described clinical and immunologic correlations of Long COVID and risk of post-vaccination infection with SARS-CoV-2 variants of concern. Dr. Jacobson is the recipient of the Burroughs Wellcome-ASTMH Fellowship in Tropical Infectious Diseases, a Thrasher Fund Early Career Award, and a National Institute of Allergy and Infectious Diseases (NIAID)-funded Mentored Patient-Oriented Research Career Development Award (K23AI177817) evaluating sequelae of maternal SARS-CoV-2 infection and vaccination on early infant outcomes in Uganda.

Current Positions

  • Research Scientist

Section Affiliations

Primary Research Interests

  • Mitigating sequelae of infectious diseases
  • SARS-CoV-2 disease

Related Websites


Impact of gestational SARS-CoV-2 and maternal inflammation on child growth and neurodevelopment in a malaria-endemic setting

Leveraging longitudinal clinical data and samples from mother-infant dyads enrolled in two ongoing NIH-funded trials in Busia, Uganda, with high incidence of malaria and SARS-CoV-2, this study will evaluate the impact of gestational SARS-CoV-2 infection and vaccination on early childhood growth and neurodevelopment, and determine if the effect of gestational SARS-CoV-2 infection and vaccination on infant outcomes is mediated by specific maternal inflammatory pathways.

Investigator: Jacobson, Karen

Funder: National Institute of Allergy and Infectious Diseases

Back To Top